Prognostic capacity of preoperative levels of selected blood inflammatory markers for glioma patient’s survival

Abstract

Glioma is considered to be a rare type of cancer of the central nervous system (CNS) with the average age-adjusted incidence rate of 3.4 per 100, 000 population. Moreover, gliomas are the most common type of malignant brain tumors among adult population. They account for about 80% of all diagnosed brain tumors originating from brain parenchyma. Despite achievements in medical treatment and technologies glioblastoma patients still have poor prognosis with 3-5% of surviving patients after 12-15 months following standard therapy. In addition, recent studies highlight importance of blood, and molecular markers in predicting presence of gliomas.